Orthofix Medical Inc.
Close on Oct 19, 2026
- Market cap
- $392.29M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 3, 2026, before market open (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 5, 2026 | Before market open | $210.90M | $-0.39 | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 5, 2026 | Before market open | $196.70M | $-0.52 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Feb 24, 2026 | Before market open | $219.90M | $-0.06 | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 4, 2025 | Before market open | $205.60M | $-0.57 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 5, 2025 | Before market open | $203.10M | $-0.36 | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 6, 2025 | Before market open | $193.60M | $-1.35 | – |
| Q4 FY2024 Ended Dec 31, 2024 | Feb 25, 2025 | Before market open | $215.70M | $-0.75 | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 7, 2024 | Before market open | $196.60M | $-0.71 | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 6, 2024 | Before market open | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 7, 2024 | Before market open | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Jan 9, 2024 | After market close | – | – | – |
Company guidance
Outlook given with results on Aug 5, 2026, compared with the previous outlook
| Measure | Period | Guidance | vs. prior |
|---|---|---|---|
| non-GAAP adjusted EBITDAnon-GAAP | full-year 2026 | $95.00M to $98.00M | Maintained |
| Net salesnon-GAAP | full-year 2026 | $845.00M to $855.00M | New |
Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.
Press releases
Announcements Orthofix Medical filed with the SEC
Orthofix Reports Second Quarter 2026 Results Reflecting Continued Operational Progress
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Drive Profitable Growth Investor Presentation August 2026
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Orthofix Reports First Quarter 2026 Results Highlighting Steady Execution Following Spine
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Drive Profitable Growth Investor Presentation May 2026
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Orthofix Realigns Spine Leadership to Strengthen Focus and Execution
Results of operations · Executive or director change · EX-99.1 to Form 8-K
Orthofix Reports Fourth Quarter and Full-Year 2025 Financial Results and
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Drive Profitable Growth Investor Presentation February 2026
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Orthofix Reports Third Quarter 2025 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Clear Course for Profitable Growth Investor Presentation November 2025
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Orthofix Reports Second Quarter 2025 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Clear Course for Profitable Growth 2Q 2025 Earnings Call August 5, 2025
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Orthofix Reports First Quarter 2025 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Clear Course for Profitable Growth 1Q 2025 Earnings Call May 6, 2025
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Orthofix Announces Appointment of Vickie Capps to Board of Directors
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Orthofix Reports Fourth Quarter and Full-Year 2024 Results and
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Clear Course for Profitable Growth 4Q and Full-Year 2024 Earnings Call February 25, 2025
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Orthofix Reports Third Quarter 2024 Results, Reiterates Full-Year 2024 Financial Guidance, and
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Clear Course for Profitable Growth Investor Presentation November 7, 2024
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Orthofix Reports Second Quarter 2024 Results and Raises Full-Year 2024 Financial Guidance
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
2nd Quarter 2024 Earnings Call August 6, 2024
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Orthofix Reports First Quarter 2024 Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
May 2024 Corporate Investor Deck
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Supplemental Financials 1Q24 Earnings May 7, 2024
Results of operations · Regulation FD disclosure · EX-99.3 to Form 8-K
Orthofix Reports Fourth Quarter and Full Year 2023 Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Corporate Investor Deck March 2024
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Supplemental Financials 4Q23 and FY23 Earnings March 5, 2024
Results of operations · Regulation FD disclosure · EX-99.3 to Form 8-K
Julie Andrews Begins as New Chief Financial Officer at Orthofix
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Orthofix Medical Inc. Announces Preliminary 2023 Fourth Quarter and Full-Year Net Sales Results
Results of operations · Executive or director change · EX-99.1 to Form 8-K
Orthofix Provides Executive Management Business Update and Appoints Julie Andrews as Chief Financial Officer
Regulation FD disclosure · EX-99.1 to Form 8-K
Orthofix Announces Agreement with Engine Capital and Appointment of Three New Independent Directors to Further Advance Position as Leading Global Spine and Orthopedics Company
Material agreement · Executive or director change · Other events · EX-99.1 to Form 8-K
Orthofix Names Massimo Calafiore as President and Chief Executive Officer
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Orthofix Reports Third Quarter 2023 Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Corporate Investor Deck November 2023
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Geoffrey Gillespie Appointed Interim Chief Financial Officer
Executive or director change · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Orthofix Reports Second Quarter 2023 Results and Raises Revenue and Adjusted EBITDA Guidance
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Corporate Investor Deck August 2023
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Orthofix Announces Changes to Board of Directors
Executive or director change · Charter or bylaw amendment · Shareholder vote results · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Orthofix Reports First Quarter 2023 Results
Results of operations · Regulation FD disclosure · EX-99 to Form 8-K
Orthofix Medical Reports Orthofix and SeaSpine Fourth Quarter and Full-Year 2022 Results
Results of operations · Regulation FD disclosure · EX-99 to Form 8-K
Orthofix Medical Inc. Announces Preliminary SeaSpine and Orthofix 2022 Fourth Quarter and Full-Year Net Sales Results
Results of operations · EX-99.1 to Form 8-K